<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2024-39-4-142-149</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-2290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Отдаленный прогноз неблагоприятных сердечнососудистых событий у пациентов с хронической сердечной недостаточностью в зависимости от полиморфизма rs1143634 гена интерлейкина-1β</article-title><trans-title-group xml:lang="en"><trans-title>Long-term prognosis of adverse cardiovascular events in patients with chronic heart failure depending on the rs1143634 polymorphism of the interleukin-1β gene</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8050-2892</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хазова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khazova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хазова Елена Владимировна, канд. мед. наук, доцент, доцент кафедры пропедевтики внутренних болезней им. профессора С.С. Зимницкого, </p><p>420012, Казань, ул. Бутлерова, 49</p></bio><bio xml:lang="en"><p>Elena V. Khazova, Cand. Sci. (Med.), Associate Professor, Department of Propaedeutics of Internal Diseases named after professor S.S. Zimnitsky,</p><p>49, Butlerov str., Kazan, 420012</p></bio><email xlink:type="simple">hazova_elena@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Казанский государственный медицинский университет Министерства здравоохранения Российской Федерации (Казанский ГМУ Минздрава России)<country>Россия</country></aff><aff xml:lang="en">Kazan State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>05</day><month>12</month><year>2024</year></pub-date><volume>39</volume><issue>4</issue><issue-title>Выпуск 2024_4</issue-title><fpage>142</fpage><lpage>149</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хазова Е.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Хазова Е.В.</copyright-holder><copyright-holder xml:lang="en">Khazova E.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/2290">https://www.sibjcem.ru/jour/article/view/2290</self-uri><abstract><p>Течение и прогноз хронической сердечной недостаточности сопряжены с активацией воспалительных каскадов, выраженность которых имеет генетическую детерминированность.</p><sec><title>Цель</title><p>Цель: анализ неблагоприятных сердечно-сосудистых событий у пациентов с хронической сердечной недостаточностью на протяжении 5 лет в зависимости от полиморфизма rs1143634 гена интерлейкина-1β.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Изучены клинические признаки, проведено генотипирование по полиморфному локусу rs1143634 гена IL-1β пациентов с хронической сердечной недостаточностью ишемического генеза (n = 445, средний возраст – 66,4 ± 10,4 года). Информация об исходах пациентов в течение 5 лет получена методом телефонного опроса по конечным точкам: смерть от всех причин, сердечно-сосудистая смерть. Смертельные и несмертельные сердечно-сосудистые события сформировали комбинированную конечную точку. Время до наступления события анализировали методом Каплана – Мейера; отношение рисков – регрессией Кокса. Статистическую обработку проводили в программах Jamovi, R 4.3.1.</p></sec><sec><title>Результаты и выводы</title><p>Результаты и выводы. Встречаемость генотипов полиморфизма rs1143634 гена IL-1β у пациентов с хронической сердечной недостаточностью и группы генетического контроля не различалась и была соразмерна с теоретически ожидаемым равновесием Харди – Вайнберга. Носители ТТ генотипа характеризовались большим уровнем воспаления, развитием инфаркта миокарда в молодом возрасте. У пациентов с хронической сердечной недостаточностью ТТ генотипа риск смерти от всех причин был выше в 2,85 раза, достижения комбинированной конечной точки – в 3,3 раза, смертельного мозгового инсульта – в 17,1 раза в сравнении с CC генотипом, в 14,9 раза – в сравнении с СТ генотипом. У пациентов с хронической сердечной недостаточностью и хронической болезнью почек ТТ генотипа риск смерти от мозгового инсульта был в 29,33 раза выше, чем у пациентов СС генотипа, в 29,12 раза – чем у пациентов СТ генотипа. У пациентов с хронической сердечной недостаточностью в сочетании с сахарным диабетом частота госпитализаций по причине декомпенсации сердечной деятельности при ТТ генотипе была выше, чем при СС и СТ генотипах (χ2 = 6,33; р = 0,042).</p></sec></abstract><trans-abstract xml:lang="en"><p>The course and prognosis of chronic heart failure (CHF) are associated with the activation of inflammatory cascades, the severity of which is genetically determined.</p><sec><title>Aim</title><p>Aim: To analyze adverse cardiovascular events in patients with chronic heart failure over 5 years depending on the rs1143634 polymorphism of the interleukin-1β gene.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. Clinical signs were studied, genotyping was carried out at the polymorphic locus rs1143634 of the IL-1β gene in patients with CHF of ischemic origin (n = 445, average age 66.4 ± 10.4 years). Information on patient outcomes over 5 years was obtained by telephone interview with endpoints: all-cause death, cardiovascular death, fatal and non-fatal cardiovascular events formed a composite endpoint. Time to event was analyzed using the Kaplan-Meier method; hazard ratio – Cox regression. Statistical processing was carried out in the Jamovi, R 4.3.1 programs.</p></sec><sec><title>Results and conclusions</title><p>Results and conclusions. The occurrence of genotypes of the rs1143634 polymorphism of the IL-1β gene in patients with CHF and the genetic control group did not differ and was commensurate with the theoretically expected Hardy–Weinberg equilibrium. Carriers of the TT genotype were characterized by a high level of inflammation and the development of myocardial infarction at a young age. In patients with CHF of the TT genotype, the risk of death from all causes is 2.85 times higher, achieving the combined endpoint is 3.3 times higher, fatal cerebral stroke is 17.1 times higher compared to CC, 14.9 times higher than compared to ST genotype. In patients with CHF and chronic kidney disease of the TT genotype, the risk of death from cerebral stroke is 29.33 times higher than the CC genotype, and 29.12 times higher for the CT genotype. In patients with CHF in combination with diabetes mellitus, the frequency of hospitalizations due to cardiac decompensation in the TT genotype is higher than in the CC and CT genotypes (χ2 = 6.33, p = 0.042).</p><p>chronic heart failure; rs1143634 polymorphism of the IL-1β gene; prognosis; cardiovascular complications</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>полиморфизм rs1143634 гена IL-1β</kwd><kwd>прогноз</kwd><kwd>кардиоваскулярные осложнения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>rs1143634 polymorphism of the IL-1β gene</kwd><kwd>prognosis</kwd><kwd>cardiovascular complications</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 2007;9(3):236–241. DOI: 10.1007/bf02938356.</mixed-citation><mixed-citation xml:lang="en">Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 2007;9(3):236–241. DOI: 10.1007/bf02938356.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Тепляков А.Т., Шилов С.Н., Попова А.А., Березикова Е.Н., Гракова Е.В., Неупокоева М.Н. и др. Роль провоспалительных цитокинов в развитии антрациклин-индуцированной сердечной недостаточности. Сибирский журнал клинической и экспериментальной медицины. 2020;35(2):66–74. DOI: 10.29001/2073-8552-2020-35-2-66-74.</mixed-citation><mixed-citation xml:lang="en">Teplyakov A.T., Shilov S.N., Popova A.A., Berezikova E.N., Grakova E.V., Neupokoeva M.N. et al. The role of proinflammatory cytokines in the development of anthracycline-induced heart failure. Siberian Journal of Clinical and Experimental Medicine. 2020;35(2):66–74. (In Russ.) DOI: 10.29001/2073-8552-2020-35-2-66-74.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fang Y., Xie H., Lin Z. Association between IL-1β + 3954C/T polymorphism and myocardial infarction risk: A meta-analysis. Medicine (Baltimore). 2018;97(30):e11645. DOI: 10.1097/MD.0000000000011645.</mixed-citation><mixed-citation xml:lang="en">Fang Y., Xie H., Lin Z. Association between IL-1β + 3954C/T polymorphism and myocardial infarction risk: A meta-analysis. Medicine (Baltimore). 2018;97(30):e11645. DOI: 10.1097/MD.0000000000011645.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tabata N., Sueta D., Akasaka T., Arima Y., Sakamoto K., Yamamoto E. et al. Helicobacter pylori seropositivity in patients with interleukin-1 polymorphism is significantly associated with ST-segment elevation myocardial infarction. PLoS One. 2016;11(11):e0166240. DOI: 10.1371/journal.pone.0166240.</mixed-citation><mixed-citation xml:lang="en">Tabata N., Sueta D., Akasaka T., Arima Y., Sakamoto K., Yamamoto E. et al. Helicobacter pylori seropositivity in patients with interleukin-1 polymorphism is significantly associated with ST-segment elevation myocardial infarction. PLoS One. 2016;11(11):e0166240. DOI: 10.1371/journal.pone.0166240.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Q., Wang W., Huang Zh., Huang D.L., Li T., Wang F. et al. Correlation of rs1122608 SNP with acute myocardial infarction susceptibility and clinical characteristics in a Chinese Han population: A case control study. The Anatolian Journal of Cardiology. 2018;19(4):249–258. DOI:10.14744/anatoljcardiol.2018.35002.</mixed-citation><mixed-citation xml:lang="en">Chen Q., Wang W., Huang Zh., Huang D.L., Li T., Wang F. et al. Correlation of rs1122608 SNP with acute myocardial infarction susceptibility and clinical characteristics in a Chinese Han population: A case control study. The Anatolian Journal of Cardiology. 2018;19(4):249–258. DOI:10.14744/anatoljcardiol.2018.35002.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Serafin M., Kalinka J. The role of chosen polymorphism of gens coding cytokines IL-1ß, IL1ra, IL-6 and TNFalpha in the pathogenesis of the preterm delivery. Ginekol i Poloznictwo.2014;33(3):9–23.</mixed-citation><mixed-citation xml:lang="en">Serafin M., Kalinka J. The role of chosen polymorphism of gens coding cytokines IL-1ß, IL1ra, IL-6 and TNFalpha in the pathogenesis of the preterm delivery. Ginekol i Poloznictwo.2014;33(3):9–23.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pociot F., Molvig J., Wogensen L., Worsaae H., Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 1992;22:396–402. DOI: 10.1111/j.1365-2362.</mixed-citation><mixed-citation xml:lang="en">Pociot F., Molvig J., Wogensen L., Worsaae H., Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 1992;22:396–402. DOI: 10.1111/j.1365-2362.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Latkovskis G., Licis N., Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur. J. Immunogenet. 2004;31(5):207–213. DOI: 10.1111/j.1365-2370.2004.00476.x.</mixed-citation><mixed-citation xml:lang="en">Latkovskis G., Licis N., Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur. J. Immunogenet. 2004;31(5):207–213. DOI: 10.1111/j.1365-2370.2004.00476.x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">rs1143634. Ensembl is a genome browser. URL: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=2:112832313-112833313;v=rs1143634;vdb=variation;vf=182624122 (08.10.2024).</mixed-citation><mixed-citation xml:lang="en">rs1143634. Ensembl is a genome browser. URL: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=2:112832313-112833313;v=rs1143634;vdb=variation;vf=182624122 (08.10.2024).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fadl M.A., Noor Аlgalil S.S. IL1 𝛽 exon 395 C/ Polymorphism potential genetic risk factor of heart diseases’ predisposition in Sudanese patients. Sudan Journal of Medical Sciences. 2020;15(4):399–407. DOI: 10.18502/sjms.v15i4.8162.</mixed-citation><mixed-citation xml:lang="en">Fadl M.A., Noor Аlgalil S.S. IL1 𝛽 exon 395 C/ Polymorphism potential genetic risk factor of heart diseases’ predisposition in Sudanese patients. Sudan Journal of Medical Sciences. 2020;15(4):399–407. DOI: 10.18502/sjms.v15i4.8162.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pan Q., Hui D., Hu C. A variant of IL1B is associated with the risk and blood lipid levels of myocardial infarction in Eastern Chinese individuals. Immunol. Invest. 2022;51(5):1162–1169. DOI: 10.1080/08820139.2021.1914081.</mixed-citation><mixed-citation xml:lang="en">Pan Q., Hui D., Hu C. A variant of IL1B is associated with the risk and blood lipid levels of myocardial infarction in Eastern Chinese individuals. Immunol. Invest. 2022;51(5):1162–1169. DOI: 10.1080/08820139.2021.1914081.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Захарьян Е.А., Грицкевич О.Ю. Влияние однонуклеотидных полиморфизмов генов IL1β, EDN1 и NOS3 на индивидуальный генетический профиль пациентов с ишемической болезнью сердца в Республике Крым. Вестник современной клинической медицины. 2023;16(6):31–36. DOI: 10.20969/VSKM.2023.16(6).31–36.</mixed-citation><mixed-citation xml:lang="en">Zakharyan E.A., Gritskevich O.Yu. The influence of single nucleotide polymorphisms of the IL1β, EDN1 and NOS3 genes on the individual genetic profile of patients with coronary heart disease in the Republic of Crimea. The Bulletin of Contemporary Clinical Medicine. 2023;16(6):31– 36. (In Russ.). DOI: 10.20969/VSKM.2023.16(6).31–36.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Топчиева Л.В., Курбатова И.В., Малышева И.Е., Корнева В.А., Топчиева А.В. Аллельный полиморфизм генов, вовлеченных в продук цию IL-1β, и предрасположенность людей к развитию артериальной гипертензии. Научные результаты биомедицинских исследований. 2023;9(1):53–70.</mixed-citation><mixed-citation xml:lang="en">Topchieva L.V., Kurbatova I.V., Malysheva I.E., Korneva V.A., Topchieva A.V. Allelic polymorphism of genes involved in IL-1β production and predisposition of people to the development of arterial hypertension. Research Results in Biomedicine. 2023;9(1):53–70. (In Russ.). DOI: 10.18413/2658-6533-2023-9-1-0-4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Маянская С.Д., Яковлева Н.Ф., Яковлев А.В., Филипенко М.Л., Воронина Е.П., Березикова Е.Н. и др. Полиморфизм генов интерлейкина-1β и рецепторного антагониста интерлейкина-1 у больных хронической сердечной недостаточностью. Журнал сердечная недостаточность. 2008;9(2):60–63.</mixed-citation><mixed-citation xml:lang="en">Mayanskaya S.D., Yakovleva N.F., Yakovlev A.V., Filipenko M.L., Voronina E.P., Berezikova E.N., et al. Polymorphism of interleukin-1β and interleukin-1 receptor antagonist genes in patients with chronic heart failure. Journal of heart failure. 2008;9(2):60–63. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Тепляков А.Т., Шилов С.Н., Березикова Е.Н., Яковлева Н.Ф., Торим Ю.Ю., Кистенева И.В. и др. Клинико-генетические детерминанты генов ФНО-ОС, ИЛ-1/3 И ИЛ-1РА в инициации и развитии хронической сердечной недостаточности у больных ишемической болезнью сердца. Сибирский медицинский журнал (Томск). 2009;24(1):40–48.</mixed-citation><mixed-citation xml:lang="en">Teplyakov A.T., Shilov S.N., Berezikova E.N., Yakovleva N.F., Torim Yu.Yu., Kisteneva I.V. et al. Clinical and genetic determinants of the genes TNF-OS, IL-1/3 AND IL-1RA in the initiation and development of chronic heart failure in patients with coronary heart disease. Siberian Medical Journal (Tomsk). 2009;24(1):40–48. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer F., Voss S., Roessig L., Igl B.W., Butler J., Lam C.S.P. et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur. J. Heart Fail. 2020;22(9):1675–1683. DOI: 10.1002/ejhf.1787.</mixed-citation><mixed-citation xml:lang="en">Kramer F., Voss S., Roessig L., Igl B.W., Butler J., Lam C.S.P. et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur. J. Heart Fail. 2020;22(9):1675–1683. DOI: 10.1002/ejhf.1787.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zeybek U., Toptas B., Karaali Z.E., Kendir M., Cakmakoglu B. Effect of TNF-α and IL-1β genetic variants on the development of myocardial infarction in Turkish population. Mol. Biol. Rep. 2011;38(8):5453–5457. DOI: 10.1007/s11033-011-0701-x.</mixed-citation><mixed-citation xml:lang="en">Zeybek U., Toptas B., Karaali Z.E., Kendir M., Cakmakoglu B. Effect of TNF-α and IL-1β genetic variants on the development of myocardial infarction in Turkish population. Mol. Biol. Rep. 2011;38(8):5453–5457. DOI: 10.1007/s11033-011-0701-x.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Coker A., Arman A., Soylu O., Tezel T., Yildirim A. Lack of association between IL-1 and IL-6 gene polymorphisms and myocardial infarction in Turkish population. Int. J. Immunogenet. 2011;38(3):2018. DOI: 10.1111/j.1744-313X.2010.00988.x.</mixed-citation><mixed-citation xml:lang="en">Coker A., Arman A., Soylu O., Tezel T., Yildirim A. Lack of association between IL-1 and IL-6 gene polymorphisms and myocardial infarction in Turkish population. Int. J. Immunogenet. 2011;38(3):2018. DOI: 10.1111/j.1744-313X.2010.00988.x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
